基本信息
views: 0
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Inge Marie Svane has more than 25 years of research experience in cancer immunology and immunotherapy and holds a PhD in basic cancer immunology. She has pioneered the field of cancer immunotherapy in Denmark, building up CCIT-DK, a translational research center in a leading European position. Her focus of expertise is T-cell based adoptive cell therapy and other cellular therapies, cancer vaccines, and immune regulation. CCIT-DK comprise a clean room (GMP) facility headed by Inge Marie Svane enabling manufacturing of in-house clinical grad immunotherapeutic products.
Since 2001 she has initiated more than 20 phase I, II, and III immunotherapeutic trials as academic sponsor. Further, she is national principal investigator on numerous international clinical trials in collaboration with the pharmaceutical industry, primarily within the area of immunotherapy. Inge Marie Svane is co-founder of IO Biotech, a spinout biotech company from Herlev and Gentofte Hospital and the Capital Region of Denmark aiming to develop immune modulating vaccines for cancer therapy. Inge Marie Svane has an extensive cooperative network with scientists and clinicians nationally and internationally and is a frequent speaker at national and international meetings, courses, and conferences.
Inge Marie Svane is key opinion leader on cancer immunotherapy, acknowledging the importance of communication to the public, patient associations, and politicians. She actively supports the European cancer patient coalition as scientific committee member in the Immuno-Oncology Academy. She is member of the scientific committee and faculty on Immunotherapy in the European Society for Medical Oncology, ESMO. Further, she is initiator of a national, scientific network, IMMUNONET, member of the European melanoma group, EORTC, and steering group member of the Danish Melanoma Group heading national treatment guidelines and real-world patient registries.
Inge Marie Svane is co-author of more than 275 scientific publications, including senior author on more than 85 papers in NEJM, Lancet Oncol, Nature Med, Cancer Res, J Immunother Cancer, Br J Cancer, Clin Cancer Res, Oncoimmunology, Eur J Cancer, Cancer Immunol Immunother, Front Immunol, Cancer Immunol Res, and Blood a.o.
Since 2001 she has initiated more than 20 phase I, II, and III immunotherapeutic trials as academic sponsor. Further, she is national principal investigator on numerous international clinical trials in collaboration with the pharmaceutical industry, primarily within the area of immunotherapy. Inge Marie Svane is co-founder of IO Biotech, a spinout biotech company from Herlev and Gentofte Hospital and the Capital Region of Denmark aiming to develop immune modulating vaccines for cancer therapy. Inge Marie Svane has an extensive cooperative network with scientists and clinicians nationally and internationally and is a frequent speaker at national and international meetings, courses, and conferences.
Inge Marie Svane is key opinion leader on cancer immunotherapy, acknowledging the importance of communication to the public, patient associations, and politicians. She actively supports the European cancer patient coalition as scientific committee member in the Immuno-Oncology Academy. She is member of the scientific committee and faculty on Immunotherapy in the European Society for Medical Oncology, ESMO. Further, she is initiator of a national, scientific network, IMMUNONET, member of the European melanoma group, EORTC, and steering group member of the Danish Melanoma Group heading national treatment guidelines and real-world patient registries.
Inge Marie Svane is co-author of more than 275 scientific publications, including senior author on more than 85 papers in NEJM, Lancet Oncol, Nature Med, Cancer Res, J Immunother Cancer, Br J Cancer, Clin Cancer Res, Oncoimmunology, Eur J Cancer, Cancer Immunol Immunother, Front Immunol, Cancer Immunol Res, and Blood a.o.
Research Interests
Papers共 547 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Stine K. Christensen, Mette L. Winther, Ida J. Laursen,Freja S. Madsen,Carsten Brink, Thomas H. Brix,Eva Ellebaek,Inge Marie Svane, Frederikke S. Hansen,Charlotte Haslund,Olivia K. Laursen,Henrik Schmidt,
SUPPORTIVE CARE IN CANCERno. 5 (2024)
Renske M. T. ten Ham,Maartje W. Rohaan,Inge Jedema,Rob Kessels, Wim Stegeman, Walter Scheepmaker,Bastiaan Nuijen,Cynthia Nijenhuis,Melanie Lindenberg,Troels Holz Borch,Tine Monberg,Marco Donia,
JOURNAL FOR IMMUNOTHERAPY OF CANCERno. 3 (2024)
Thomas Morgan Hulen, Christina Friese,Nikolaj Pagh Kristensen,Joachim Stoltenborg Granhøj,Troels Holz Borch,Marlies J. W. Peeters,Marco Donia,Mads Hald Andersen, Sine Reker Hadrup,Inge Marie Svane, Özcan Met, Özcan Met
Frontiers in Immunology (2024)
ANNALS OF SURGICAL ONCOLOGYno. 1 (2024): S32-S32
Cited0Views0Bibtex
0
0
Keith Henry Moss,Ulla Kring Hansen, Vinicius Araújo Barosa de Lima,Annie Borch, Esteban Sanchez Marquez,Anne-Mette Bjerregaard,Østrup Olga,Amalie Kai Bentzen,Andrea Marion Marquard, Mohammed kadivar,Inge Marie Svane,Ulrik Lassen,
crossref(2024)
Sif Homburg,Charlotte Birk Christensen,Magnus Pedersen, Simon Grund Sorensen,Marco Donia,Inge Marie Svane,Helle Westergren Hendel,Eva Ellebaek
CANCERSno. 5 (2024)
Stine K. Christensen, Mette L. Winther, Ida J. Laursen,Freja S. Madsen,Carsten Brink, Thomas H. Brix,Eva Ellebaek,Inge Marie Svane, Frederikke S. Hansen,Charlotte Haslund,Olivia K. Laursen,Henrik Schmidt,
Supportive Care in Cancerno. 5 (2024)
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn